Drug Trial Radar · NCT06863636
Efficacy and Safety of Celecoxib/Acetaminophen Versus Celecoxib for Diagnosed Osteoarthritis in Acute Exacerbation
Last checked: Nov 20, 2026Latest source record: Oct 23, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
231
Actual
Start
Sep 9, 2024
Primary completion
Oct 30, 2025
Study completion Nov 30, 2025
Sponsor
- Lead sponsor
- Laboratorios Silanes S.A. de C.V.Industry
- Sponsor type
- Industry
- First posted
- Mar 7, 2025
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Double (participant, investigator)
- Primary purpose
- Treatment
- FDA-regulated drug
- No
- Who can join
- All sexes, from 40 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This is a Phase III, longitudinal, multicenter, randomized, double-blind clinical trial designed to evaluate the efficacy and safety of a fixed-dose combination of celecoxib and acetaminophen compared to celecoxib monotherapy for the treatment of pain associated with acute exacerbations of osteoarthritis.
Conditions
- Joint Pain
- Knee Osteoarthritis
- Hip Osteoarthritis
Interventions
Celecoxib + AcetaminophenDrug
One tablet of 200 mg / 200 mg a day
Celecoxib + AcetaminophenDrug
One tablet of 200 mg / 500 mg a day
CelecoxibDrug
One capsule of 200 mg a day
Primary outcomes
What the sponsor says the trial is designed to measure.
- Comparison of the proportion of patients in each treatment group who, based on the baseline assessment, achieved a response according to the OMERACT-OARSI criteria at Weeks 1, 2, 4, and 6 of follow-up.Time frame: 6 weeks
- Number of participants Number of participants reporting treatment-related adverse events, as recorded in the patient diary.treatment-related adverse events through the patient's diary record.Time frame: 6 weeks
Locations
1 site in 1 country. Site status is shown where the registry gives one.
Laboratorio Silanes, S.A. de C.V.
Mexico City, Mexico City, Mexico
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.